“US Orphan Drug Market Outlook 2018” Research Report Highlights:  Number of Marketed orphan Drugs: 222  Orphan Drug in Clinical Pipeline: 501  US Orphan Drug Market Overview  Orphan Drug Designation Criteria  Market Specific Reimbursement Policy & Regulatory Framework  US Orphan Drug Pipeline by Phase, Indication & Originator

1. US Orphan Drug Market To Surpass USD 60 Billion by 2018
With factors like government support, high profitability and many more, this market is
expected to grow at CAGR of 5%.
“US Orphan Drug Market Outlook 2018” Research Report Highlights:
 Number of Marketed orphan Drugs: 222
 Orphan Drug in Clinical Pipeline: 501
 US Orphan Drug Market Overview
 Orphan Drug Designation Criteria
 Market Specific Reimbursement Policy & Regulatory Framework
 US Orphan Drug Pipeline by Phase, Indication & Originator
In the largest market for orphan drugs, USA, there was a shortage of adequate therapies for
treating many rare diseases. These therapies were not developed as companies did not expect
these drugs to be highly profitable. Hence there was a lack of interest and thus investment on
the part of pharma companies in the USA. Therefore, the FDA introduced incentives for
developing such drugs. This step taken by the FDA was successful in creating a thriving market
for orphan drugs.
It was in the USA first that a special law exclusively for governing orphan drugs was framed in
the form of the Orphan Drug Act of 1983. This led to an increase in the popularity of orphan
drugs. The FDA also has been continuously increasing its efforts to support this market by
providing significant financial and non-financial incentives to the pharmaceutical companies
to attract them. This has been one of the major drivers of growth for the US orphan drugs
market.
For Report Sample Visit: US Orphan Drug Market Outlook 2018
Or Contact: avinash@kuickresearch.com